Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.
Drs Roy Herbst and David Rimm review how biomarker testing has transformed the way patients with lung cancer are treated, and how both medical oncologists and pathologists contribute to these changes.
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.
Dr Wainberg and Dr Gerson talk about the efficacy limitations of cytotoxic chemotherapy on some cells for a variety of reasons.
Dr Gerson offers insights into the various aspect’s of stem cells, including the ability to replicate, rest, and spread to different locations.
Dr Gerson discusses the process in which genetic changes cause tumors to grow.
Dr Wainberg and Dr Gerson talk about the two different cell types that lead to metastasis and the process of stem cell growth.
Dr Wainberg and Dr Gerson discuss features of stem cells and how in understanding their features they can be targeted for therapeutics.
Dr Wainberg and Dr Gerson discuss how biomarkers may help identify cancer stem cells.